Currently out of the existing stock ratings of Jeet Mukherjee, 67 are a BUY (100%).

Jeet Mukherjee

Work Performance Price Targets & Ratings Chart

Analyst Jeet Mukherjee, currently employed at BTIG, carries an average stock price target met ratio of 16.98% that have a potential upside of 29.76% achieved within 73 days.

Jeet Mukherjee’s has documented 132 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VSTM, Verastem.

Wall Street Analyst Jeet Mukherjee

Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 9/9/2025. The price target of $87 was fulfilled within 23 days with a profit of $42.07 (93.63%) receiving and performance score of 40.71.

Average potential price target upside

ARVN Arvinas CATX Perspective Therapeutics KYMR Kymera Therapeutics MNPR Monopar Therapeutics NRIX Nurix Therapeutics VSTM Verastem AVBP ArriVent BioPharma BCAX Bicara Therapeutics IBRX Immunitybio IPHA Innate Pharma SNSE Sensei Biotherapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 05-Mar-2026

$21

$14.03 (201.29%)

$24

2 months 12 days ago
(10-Aug-2026)

8/22 (36.36%)

$12.01 (133.59%)

106

Buy Since 25-Feb-2026

$14

$7.03 (100.86%)

$19

2 months 12 days ago
(10-Aug-2026)

0/2 (0%)

$5.01 (55.73%)

Hold Since 18-Sep-2025

$12

$5.03 (72.17%)

$11

2 months 17 days ago
(05-Aug-2026)

12/19 (63.16%)

$3.6 (42.86%)

129

Buy Since 09-May-2024

$11

$4.03 (57.82%)

$15

2 months 17 days ago
(05-Aug-2026)

1/8 (12.5%)

$2.6 (30.95%)

400

Buy Since 12-Mar-2025

$18

$11.03 (158.25%)

$18

2 months 18 days ago
(04-Aug-2026)

0/7 (0%)

$9 (100.00%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Jeet Mukherjee most bullish on?

Potential upside of $63.73 has been obtained for MNPR (MONOPAR THERAPEUTICS)

Which stock is Jeet Mukherjee most reserved on?

Potential downside of $2.82 has been obtained for IBRX (IMMUNITYBIO)

What Year was the first public recommendation made by Jeet Mukherjee?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?